Q-omics provides the consensus-scored RPS12 profile across patient tissues and cancer cell-line models. RPS12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPS12 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RPS12 protein abundance shows 33,362 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, LIHC, and PDAC as cancer lineages where RPS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS12 survival associations across molecular data types. RPS12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS12 RNA expression–survival associations across cancer types. High RPS12 expression shows unfavorable associations in KIRP, ACC, LIHC and CESC, but favorable associations in UVM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPS12 RNA expression.
This table summarizes RPS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS12 shows lower tumor expression in UCEC and BRCA and higher tumor expression in LIHC, COAD, CHOL and KIRC. The LIHC box plot shows higher RPS12 RNA expression in tumor versus normal tissue (log2 FC = +0.918, t-test p < 0.001).
This table shows molecular features associated with RPS12 in patient tissues and cancer cell lines. In patient samples, RPS12 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
